Pharmaceuticals, Biotechnology and Life Sciences
Affluent Medical, a French clinical-stage medical technology company specializing in the international development and industrialization of implantable innovative medical devices, reported a net loss of €9.4 million in H1 2024, compared to a net loss of €8.0 million in the prior year period, citing several majors steps developing its three medical devices.
Oxford Drug Design is among the first three companies to be awarded a share of a £3 million Collaborative Discovery Programme (CDP) announced by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate.
Laverock Therapeutics, a UK-based gene-silencing company with a technology for the development of programmable advanced therapies to tackle major diseases,…
Bio-Sourcing, a pioneering Belgian biotherapeutic company, has secured €2.5M in grants and €10M in equity from the European Innovation Council…
SLEEVER®, a French family-owned group International SME and innovative leader in shrinksleeve label technology, and CARBIOS, (Euronext Growth Paris : ALCRB), a pioneer in the…
InflaRx N.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today said that Vilobelimab demonstrates significant improvement in reduction of draining tunnels, total lesion count, International Hidradenitis Suppurativa Score 4 and the newly introduced modified-HiSCR
Researchers from the Wellcome Sanger Institute and their collaborators focused on the ‘cancer protection’ gene RAD51C, known to increase ovarian cancer risk six-fold and risk of aggressive subtypes of breast cancer four-fold. They found over 3,000 harmful genetic changes that could potentially disrupt its function and increase cancer risk. These findings were confirmed by analysing data from large-scale health databases.
Exscientia has made a deal to acquire GT Apeiron’s share of its oral CDK7 inhibitor programme, gaining full control of…
Swedish specialist in temperature-sensitive pharmaceutical shipments, Envirotainer, has announced significant enhancements to its testing capabilities, with the addition of three…
Cresset, an innovative provider of integrated in silico solutions for drug discovery, has completed its SOC 2Type 1 audit, achieving compliance with the leading industry standards for customer data security.